Characterizing the Tumor Response to Treatment with Combretastatin A4 Phosphate

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 2007 Apr 24

PMID 17448875

Citations 21

Authors

Beth A Salmon

Dietmar W Siemann

Affiliations

Soon will be listed here.

Abstract

Purpose: To examine the pathophysiologic impact of treatment with combretastatin A4 phosphate (CA4P) in regions of tumors that ultimately either necrose or survive treatment with this agent.

Methods And Materials: Proliferation, perfusion, vessel density, and expression of vascular endothelial growth factor (VEGF) were analyzed in the KHT tumor model after treatment with CA4P. Analyses were conducted in the whole tumor and the tumor periphery.

Results: Perfusion in the tumor periphery decreased 4 h after treatment, but returned to baseline 20 h later. Whole-tumor perfusion also decreased 4 h after treatment, but did not return to baseline. Vessel density decreased in the tumor as a whole, but not in the tumor periphery. No significant effect on the expression of VEGF was observed, but a decrease in proliferation in the whole tumor and the periphery was noted.

Conclusions: The present study shows that those areas of a tumor that survive treatment with CA4P are affected by CA4P exposure, though only transiently. The decrease in perfusion could negatively affect therapies utilizing the combination of CA4P and conventional anticancer agents by decreasing drug delivery and tissue oxygenation. These findings suggest that the timing of CA4P treatments when used in conjunction with conventional anticancer therapies should be considered carefully.

Citing Articles

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.

Sidorenko V, Scodeller P, Uustare A, Ogibalov I, Tasa A, Tshubrik O Sci Rep. 2024; 14(1):17513.

PMID: 39080306 PMC: 11289491. DOI: 10.1038/s41598-024-64610-7.

Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.

Kim M, Shin J, Kim J, Son K, Kim Y, Jung C BMC Cancer. 2020; 20(1):1057.

PMID: 33143663 PMC: 7607852. DOI: 10.1186/s12885-020-07566-x.

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate.

Holmes T, Brown A, Suggitt M, Shaw L, Simpson L, Harrity J Sci Rep. 2020; 10(1):9926.

PMID: 32555222 PMC: 7303175. DOI: 10.1038/s41598-020-66568-8.

Spatial Characterization of Tumor Perfusion Properties from 3D DCE-US Perfusion Maps are Early Predictors of Cancer Treatment Response.

El Kaffas A, Hoogi A, Zhou J, Durot I, Wang H, Rosenberg J Sci Rep. 2020; 10(1):6996.

PMID: 32332790 PMC: 7181711. DOI: 10.1038/s41598-020-63810-1.

Structure Guided Design, Synthesis, and Biological Evaluation of Novel Benzosuberene Analogues as Inhibitors of Tubulin Polymerization.

Niu H, Strecker T, Gerberich J, Campbell 3rd J, Saha D, Mondal D J Med Chem. 2019; 62(11):5594-5615.

PMID: 31059248 PMC: 6925959. DOI: 10.1021/acs.jmedchem.9b00551.

References

Chaplin D, Dougherty G . Tumour vasculature as a target for cancer therapy. Br J Cancer. 1999; 80 Suppl 1:57-64. View

Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S . Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-80. PMC: 1876882. DOI: 10.1016/S0002-9440(10)65006-7. View

Kanthou C, Tozer G . The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood. 2002; 99(6):2060-9. DOI: 10.1182/blood.v99.6.2060. View

Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain R, McDonald D . Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002; 160(3):985-1000. PMC: 1867175. DOI: 10.1016/S0002-9440(10)64920-6. View

Siemann D, Mercer E, Lepler S, Rojiani A . Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 2002; 99(1):1-6. DOI: 10.1002/ijc.10316. View

Rojiani A, Li L, Rise L, Siemann D . Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol. 2002; 41(1):98-105. DOI: 10.1080/028418602317314136. View

Siemann D, Rojiani A . Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002; 53(1):164-71. DOI: 10.1016/s0360-3016(02)02742-6. View

Tozer G, Kanthou C, Parkins C, Hill S . The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2002; 83(1):21-38. PMC: 2517662. DOI: 10.1046/j.1365-2613.2002.00211.x. View

Siemann D, Rojiani A . Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002; 54(5):1512-7. DOI: 10.1016/s0360-3016(02)03919-6. View

10.

Horsman M, Murata R . Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys. 2003; 57(4):1047-55. DOI: 10.1016/s0360-3016(03)00769-7. View

11.

Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald D . Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2003; 163(5):1801-15. PMC: 1892429. DOI: 10.1016/S0002-9440(10)63540-7. View

12.

Thorpe P . Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004; 10(2):415-27. DOI: 10.1158/1078-0432.ccr-0642-03. View

13.

Siemann D, Chaplin D, Horsman M . Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004; 100(12):2491-9. DOI: 10.1002/cncr.20299. View

14.

Sheng Y, Hua J, Pinney K, Garner C, Kane R, Prezioso J . Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer. 2004; 111(4):604-10. DOI: 10.1002/ijc.20297. View

15.

Bilenker J, Flaherty K, Rosen M, Davis L, Gallagher M, Stevenson J . Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res. 2005; 11(4):1527-33. DOI: 10.1158/1078-0432.CCR-04-1434. View

16.

Tozer G, Kanthou C, Baguley B . Disrupting tumour blood vessels. Nat Rev Cancer. 2005; 5(6):423-35. DOI: 10.1038/nrc1628. View

17.

Siemann D, Rojiani A . The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys. 2005; 62(3):846-53. DOI: 10.1016/j.ijrobp.2005.02.048. View

18.

Gaya A, Rustin G . Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol). 2005; 17(4):277-90. DOI: 10.1016/j.clon.2004.11.011. View

19.

Bouis D, Kusumanto Y, Meijer C, Mulder N, Hospers G . A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res. 2005; 53(2):89-103. DOI: 10.1016/j.phrs.2005.10.006. View

20.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View